References
- Bacci M, Capobianco A, Monno A, et al. (2009). Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol 175:547–56.
- Danhier F. (2016). To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244:108–21.
- Davis ME, Zhuo GC, Dong MS. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82.
- Gustafson HH, Holt-Casper D, Grainger DW, et al. (2015). Nanoparticle uptake: the phagocyte problem. Nano Today 10:487–510.
- Hatakeyama H, Akita H, Harashima H. (2013). The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biologic Pharmaceut Bullet 36:892–9.
- Khalid A, Persano S, Shen H, et al. (2016). Strategies for improving drug delivery: nanocarriers and microenvironmental priming. Expert Opin Drug Deliv 14:1.
- Knop K, Hoogenboom R, Fischer D, et al. (2010). Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angewandte Chemie 49:6288–308.
- Michor F, Liphardt J, Ferrari M, et al. (2011). What does physics have to do with cancer? Nat Rev Cancer 11:657.
- Moghimi SM, Andersen AJ, Hashemi SH, et al. (2010). Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release 146:175–81.
- Moghimi SM, Simberg D. (2017). Complement activation turnover on surfaces of nanoparticles. Nano Today 15:8–10.
- Parodi A, Quattrocchi N, Al VDV, et al. (2013). Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nature Nanotech 8:61.
- Piaggio F, Kondylis V, Pastorino F, et al. (2016). A novel liposomal clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. J Control Release 223:165–77.
- Radi ZA, Koza-Taylor PH, Bell RR, et al. (2011). Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol 179:240–7.
- Samuelsson E, Shen H, Blanco E, et al. (2017). Contribution of kupffer cells to liposome accumulation in the liver. Colloids Surf B Biointerfaces 158:356–62.
- Tavares AJ, Poon W, Zhang YN, et al. (2017). Effect of removing kupffer cells on nanoparticle tumor delivery. Proc Natl Acad Sci USA 114:E10871–80.
- Van RN, Hendrikx E. (2010). Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 605:189–203.
- van Rooijen N, Hendrikx E. 2010. Liposomes for specific depletion of macrophages from organs and tissues. In: Weissig V, ed. Liposomes: methods and protocols, vol. 1: pharmaceutical nanocarriers. Totowa, NJ: Humana Press, 189–203.
- Wang H, Zhao Y, Wang H, et al. (2014). Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. J Control Release 192:47–56.
- Wilhelm S, Tavares AJ, Dai Q, et al. (2016). Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1:16014.
- Wolfram J, Nizzero S, Liu H, et al. (2017). A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery. Sci Rep 7:13738.
- You HB, Park K. (2011). Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153:198–205.
- Zhan X, Jia L, Niu Y, et al. (2014). Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Biomaterials 35:10046.